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ABSTRACT
Objective Cancer stem cells (CSCs) are responsible for
tumour formation and spreading, and their targeting is
required for tumour eradication. There are limited
therapeutic options for advanced colorectal cancer
(CRC), particularly for tumours carrying RAS-activating
mutations. The aim of this study was to identify novel
CSC-targeting strategies.
Design To discover potential therapeutics to be
clinically investigated as single agent, we performed a
screening with a panel of FDA-approved or
investigational drugs on primary CRC cells enriched for
CSCs (CRC-SCs) isolated from 27 patients. Candidate
predictive biomarkers of efﬁcacy were identiﬁed by
integrating genomic, reverse-phase protein microarray
(RPPA) and cytogenetic analyses, and validated by
immunostainings. DNA replication stress (RS) was
increased by employing DNA replication-perturbing or
polyploidising agents.
Results The drug-library screening led to the
identiﬁcation of LY2606368 as a potent anti-CSC
agent acting in vitro and in vivo in tumour cells from a
considerable number of patients (∼36%). By inhibiting
checkpoint kinase (CHK)1, LY2606368 affected DNA
replication in most CRC-SCs, including RAS-mutated
ones, forcing them into premature, lethal mitoses.
Parallel genomic, RPPA and cytogenetic analyses
indicated that CRC-SCs sensitive to LY2606368
displayed signs of ongoing RS response, including the
phosphorylation of RPA32 and ataxia telangiectasia
mutated serine/threonine kinase (ATM). This was
associated with mutation(s) in TP53 and hyperdiploidy,
and made these CRC-SCs exquisitely dependent on
CHK1 function. Accordingly, experimental increase of
RS sensitised resistant CRC-SCs to LY2606368.
Conclusions LY2606368 selectively eliminates
replication-stressed, p53-deﬁcient and hyperdiploid
CRC-SCs independently of RAS mutational status.
These results provide a strong rationale for
biomarker-driven clinical trials with LY2606368
in patients with CRC.
Signiﬁcance of this study
What is already known on this subject?
▸ Cancer stem cells (CSCs), the subpopulation of
cells driving tumour initiation and spreading,
are associated with cancer relapse, therapeutic
resistance and poor patient prognosis thereby
limiting the efﬁcacy of antineoplastic regimens.
▸ Patient-derived cancer models enriched for
CSCs are successfully employed for discovering
novel cancer drugs, predicting the clinical
efﬁcacy of novel antineoplastic regimens and
rapidly translating these novelties into the
clinical setting.
▸ We and others previously showed that the
therapeutic resistance of CSCs is due to their
high efﬁciency in activating the DNA damage
response (DDR) in the presence of DNA lesions,
but further investigations are required to
elucidate the status and molecular mechanisms
of DDR in CSCs and how these insights can be
exploited for cancer therapy.
▸ Previous evidence indicated that the inhibition
of the ataxia telangiectasia mutated serine/
threonine kinase (ATM)-checkpoint kinase
(CHK)2 or ataxia telangiectasia mutated and
Rad3 related serine/threonine kinase
(ATR)-CHK1 axis of DDR, alone or in
combination with DNA-damaging
chemotherapeutics, could kill cancer cells
displaying genomic instability, but the effect on
CSC survival needs further investigations.
What are the new ﬁndings?
▸ We identiﬁed LY2606368 as a potent in vitro
and in vivo anti-CSC agent able to kill a
signiﬁcant fraction (approximately a third) of
our large panel of primary colorectal cancer
(CRC) cells enriched for CSCs (CRC-SCs).
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INTRODUCTION
The management of patients with colorectal cancer (CRC)
remains a major clinical challenge, owing to the high incidence
of tumour relapse and development of treatment-refractory dis-
eases.1 Despite the discovery of novel regimens combining bio-
logical therapies to the chemotherapy backbone over the past
decade, intrinsic and acquired resistance remains a critical
hurdle. The mechanisms of therapeutic resistance, often emer-
ging after initial tumour responses, include (but are not limited
to) mutation(s) in the gene encoding the target protein,2 induc-
tion of bypass or parallel cascade(s),3 restoration of the defective
targeted pathway4 and outgrowth of pre-existing minor or
dormant clones.5
The development of effective therapeutics against solid malig-
nancies is further hampered by their considerable genetic, epi-
genetic, functional and phenotypical heterogeneity over space
and time.6–8 This intratumour heterogeneity is reported to arise
early in the development of CRC and feeds therapeutic resist-
ance.9 Mounting evidence indicates that intratumour heterogen-
eity and therapeutic resistance is driven by transient/stable
subsets of immature, undifferentiated cells known as cancer stem
cells (CSCs).6 10 11 CSCs have been isolated from multiple malig-
nancies, including CRC, by speciﬁc cell-surface markers or
serum-free in vitro culture enrichment.12 13 This stem-like popu-
lation is at the apex of the hierarchical organisation of the cancer
system, where it constitutes a perpetual pool generating non-
tumorigenic progeny with variable degree of differentiation and
plasticity, and in dynamic crosstalk with the tumour microenvir-
onment.10 CSCs are responsible for tumour initiation, and are
involved in cancer progression, recurrence, metastasis and thera-
peutic failure.10 14 15 Underscoring their clinical importance, spe-
ciﬁc CSC-related gene-expression signatures have been associated
to inferior clinical outcomes,6 16 17 and CRC patients with stem
cell-like tumours have been documented to display lower 5-year
disease-free survival rates than those having differentiated
tumours.18 The therapeutic targeting of CSCs is thus advocated
as essential for the development of effective drugs.
Multicellular spheroids (best known as tumourspheres) are a
cancer model employed to efﬁciently purify, enrich and propa-
gate patient-derived CSCs,13 hence representing a powerful tool
for discovering anticancer drugs and companion predictive bio-
markers. Considering the enormous potential of CSC-based
assays as hypothesis-generating models for early clinical trials,
we decided to screen freshly generated patient-derived CRC
tumourspheres enriched for CSCs (hereafter referred to as
CRC-SCs) with a panel of >300 drugs already approved or in
clinical development.
MATERIALS AND METHODS
Cell lines, culture conditions and chemicals
Unless otherwise indicated, media, supplements and plasticware
were purchased from Gibco-Thermo Fisher Scientiﬁc (Waltham,
Massachusetts, USA) or Corning-Life Sciences (Corning, New York,
USA). CSC isolation and culture from samples of human patients
with CRC (obtained in accordance with the standards of the institu-
tional Ethics Committee on human experimentation, authorisation
CE5ISS-09/282) were performed as previously reported19 and
described in online supplementary information. All CRC-SCs were
validated for their capability to generate neoplasms faithfully phe-
nocopying the original patient tumour when xenotransplanted into
immunocompromised mice.20 Selected CRC-SCs belonging to the
three categories (#1 and #4 for high; #3 and #6 for medium; and
#8, #10 and #12 for low sensitive) were employed in most in
vitro experiments. Of these CRC-SCs, #1, #3 and #8 were used in
vivo. Additional CRC-SCs were employed depending on cell avail-
ability and status always being well balanced towards the point of
LY2606368 sensitivity. Compounds were provided from Selleck
Chemicals (Houston, Texas, USA) with the exception of aphidico-
lin, colchicine, Mps1-IN-3, nocodazole, reversine, thymidine,
UCN-01 (all purchased from Sigma-Aldrich), LY2606368 (also
known as prexasertib, provided from Eli Lilly, Indianapolis,
Indiana, USA) and PV1019 (obtained from Calbiochem-Merck
Millipore, Billerica, Massachusetts, USA).
Compound screening and measurement of cell proliferation/
viability
To determine the IC50 or drug-combination efﬁciency, disso-
ciated cells were seeded in 96-well plates (6×103 cells/100 mL
medium/well), cultured for 24 hours and then treated as indi-
cated in the ﬁgure legends. Cell viability/proliferation was deter-
mined by evaluating the ATP levels via CellTiter-Glo
Luminescent Cell Viability Assay (Promega, Madison,
Wisconsin, USA) with a multimode reader (DTX-880; Beckman
Coulter, Brea, California, USA). For drug screening, CRC-SCs
Signiﬁcance of this study
▸ The mechanism of CRC-SC killing by LY2606368 involves the
speciﬁc inhibition of CHK1, which alters the DNA replication
and intra-S checkpoint of CRC-SCs, in turn resulting in the
generation of an intolerable DNA damage burden and the
consequent cell demise via replication catastrophe.
▸ The fraction of CRC-SCs displaying signs of DNA replication
stress, such as phosphorylation of RPA32 or ATM, deﬁciency
in p53 and increased number of chromosomes
(hyperdiploidy) was shown to be highly dependent on CHK1
activity and thus targetable with CHK1 inhibitors.
▸ Boosting replication stress or increasing the number of
chromosomes by employing DNA replication-perturbing or
mitosis-perturbing agents was proven to be a strategy to
sensitise formerly resistant CRC-SCs to LY2606368.
How might it impact on clinical practice in the
foreseeable future?
▸ Our results, together with the recent evidence on tolerable
safety proﬁles and preliminary antineoplastic activity of
LY2606368 as monotherapy in a phase I, non-randomised,
open-label, dose-escalation trial in patients affected by
advanced or metastatic solid tumours who underwent at
least three previous lines of treatment, support the further
clinical development of LY2606368.
▸ The selective targeting of CHK1 by LY2606368 can be
rapidly translated into the clinical settings for the eradication
of tumours with replication-stressed, p53-deﬁcient and
hyperdiploid CRC-SCs, which can be easily identiﬁed by p53
sequencing combined with immunohistochemical analysis for
replication stress markers (phosphorylation of ATM and
RPA32) and ploidy status (measurement of nuclear area).
▸ Our ﬁndings also guide for the further development of
therapeutic regimens based on the induction of replication
stress in patients with low DNA replication-stressed CRC
(identiﬁed as reported above) so as to broaden the
therapeutic use of LY2606368 to a large number of subjects.
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were seeded onto 96-well plates. Triplicate plates for each
CRC-SC/drug-library plate combination were generated. Upon
treatment for 72 hours, CRC-SC proliferation/viability was
determined by CellTiter-Glo assay. Normalised viability for each
drug (VD) was obtained, for each plate, by referencing lumines-
cence values (LD) to the averaged luminescence values of
Dimethyl sulfoxide (DMSO)/controls (mLC) using the formula:
VD=(LD/mLC)×100. The z scores (ZD) were calculated by ref-
erencing each normalised viability replicate (VD) to the grand
mean (Gm) and grand SD (Gsd) of all compounds using the
formula: ZD=(VD-Gm)/Gsd. Drug screening data were ana-
lysed using the ‘R’ software (R-Foundation for Statistical
Computing, Vienna, Austria).
Genetic and reverse-phase protein microarray analyses
For targeted deep DNA resequencing, the sequencing library
was prepared with the Truseq Custom Amplicon Kit (Illumina,
San Diego, California, USA), while sequencing was performed
on a MiSeq instrument. FASTQ ﬁles were analysed with Miseq
Reporter software using the somatic variant caller algorithm,
and variant annotation was performed with the VariantStudio
suite (all from Illumina). The OncoPrint was generated using
custom ‘R’ scripting and complex heatmaps library (https://
github.com/jokergoo/ComplexHeatmap). Microsatellite instabil-
ity (MSI) analysis was performed with a reference panel of ﬁve
ﬂuorescent dye-labelled microsatellite primers (NR-21, BAT-25,
MONO-27, NR-24, BAT-26) using the MSI Analysis System kit,
Version_1.2 (Promega). Ampliﬁed fragments were detected by
loading the PCR products for capillary electrophoresis using the
ABI Prism 3500 Genetic Analyser and the POP-4 polymer (both
from Applied Biosystems, Foster City, California, USA) accord-
ing to manufacturer’s instructions (Promega). MSI status was
determined upon analysis with GeneMapper software,
Version_4.1 (Applied-Biosystems). Reverse-phase protein micro-
array (RPPA) was performed as previously described.21
In vivo study
For xenograft studies, CRC-SCs were resuspended in 50%
Matrigel Basement Membrane Matrix (BD Biosciences, Franklin
Lakes, New Jersey, USA)/50% growth medium, and 5×105 cells
were injected subcutaneously in the ﬂank of mice as reported by
De Angelis et al.20 When tumours were palpable (after 3/
5 weeks), mice were randomised to control and treatment
groups (10 mice/group) and treated subcutaneously with vehicle
only (Captisol; CyDex Pharmaceuticals, La Jolla, California,
USA), or 5 or 10 mg/kg of the mesylate salt formulation of
LY2606368 (which has comparable in vitro activity and
increased in vivo bioavailability). For in vivo rescue studies,
CRC-SC-derived xenografts were harvested from vehicle-treated
or LY2606368-treated mice (6 tumours/group), dissociated as
single cells and injected into secondary mice as described above.
All animals were left untreated and in vivo tumour growth and
volumes were measured as reported by De Angelis et al.20
Immunohistochemistry (IHC)
Sections from formalin-ﬁxed/parafﬁn-embedded
CRC-SC-derived xenografts were stained as described in online
supplementary information. Images were obtained using an
Eclipse 55i microscope (Nikon, Melville, New York, USA)
equipped with Eureka Interface System (Menarini, Florence,
Italy). The levels of ataxia telangiectasia mutated serine/threo-
nine kinase (ATM) and replication protein A (RPA)32 phosphor-
ylation were evaluated in terms of proportion of expressing
tumour cells (0–100%) and staining intensity (0:negative, 1+:
weak, 2+:moderate, 3+:strong) and analysed as categorical
variables. The two scores were multiplied (maximum=300) and
the median score of all tumours was used to classify low-
expressing and high-expressing CRC-SC-derived xenografts.
Statistical procedures
Unless otherwise speciﬁed, all experiments were performed in
triplicate parallel instances and independently repeated at least
three times, data were analysed with Microsoft Excel
(Microsoft, Redmond, Washington, USA), GraphPad Prism
(GraphPad Software, San Diego, California, USA) or ‘R’ soft-
ware. Statistical signiﬁcance of data from most in vitro and in
vivo studies was evaluated by one-way or two-way ANOVA and
Bonferroni multiple comparisons test (ﬁgures 1, 5, 7 and online
supplementrary ﬁgures S2, S5–S9). Statistical analyses of RPPA
and COMET data were performed by: Kruskal-Wallis non-
parametrical test followed by Wilcoxon signed-rank test and
p value adjustment using Benjamini-Hochberg’s correction
(false discovery rate, FDR); and/or factorial ANOVA (type-III
sums of squares) followed by Tuckey’s honestly signiﬁcant differ-
ence (HSD) multiple comparison’s test (ﬁgures 3, 4, 5 and
online supplementary ﬁgures S4 and S10). The Pearson’s χ2 test
and Fisher’s exact test, when appropriate, were applied to evalu-
ate the relationship between LY2606368 sensitivity and the
phosphorylation of RPA32, ATM, the ploidy status, MSI status
and tumour protein 53 (TP53/p53) mutational status (ﬁgures 4,
6 and online supplementary text) with SPSS software
Version_21 (SPSS, Chicago, Illinois, USA).
The detailed description of all materials and methods are
reported in online supplementary information.
RESULTS
Identiﬁcation of the checkpoint kinase (CHK)1/CHK2
inhibitor LY2606368 as a potent in vitro and in vivo
anti-CSC agent
To discover novel compounds targeting CSCs, we took advan-
tage of a large collection of primary CRC-SCs12 characterised
for the mutational status of recurrently CRC-altered genes,
whose mutational frequency is consistent with that reported in
The Cancer Genome Atlas (TCGA) (see online supplementary
table S1) (http://cancer.sanger.ac.uk/cosmic/).22 Throughout this
study only early passage CRC-SCs were used.
For the initial screening, we selected three CRC-SCs differing
for Kirsten rat sarcoma viral oncogene homolog (KRAS) status,
one wild type (#1) and two mutated (#2 and #3). Moreover, we
manually curated a library of 305 clinically relevant (as mostly
US Food and Drug Administration (FDA)-approved or investiga-
tional) compounds targeting most cancer-related pathways (see
online supplementary table S2). CRC-SCs were treated with the
full drug library at 20 nM and assessed 72 hours later for their
proliferation/viability by measuring ATP levels. This high-
throughput drug-sensitivity assay allowed us to identify three
compounds exerting the most potent anti-CSC activity
(ﬁgure 1A). The novel CHK1-CHK2 inhibitor LY260636823 was
selected for further investigation, considering that: (1) the
ATM-CHK2 and ATM and Rad3 related serine/threonine kinase
(ATR)-CHK1 axes of the DNA damage response (DDR) were
shown to be involved in CSC therapeutic resistance;24 25 and (2)
LY2606368 demonstrated acceptable safety proﬁle and prelimin-
ary evidence of antineoplastic activity in a recent phase I,
dose-expansion study,26 and is being employed in ongoing phase
I and phase II clinical trials (https://clinicaltrials.gov/).
Further conﬁrming its potent anti-CRC-SC activity, in a
dose-response study LY2606368 resulted the most effective
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DDR inhibitor in killing CSCs (IC50<13 nM in four out of ﬁve
CRC-SCs) (ﬁgure 1B and online supplementary ﬁgure S1).
When we extended our analyses to multiple CRC-SCs, we con-
ﬁrmed the dose-dependent and time-dependent anti-CRC-SC
activity of LY2606368, and classiﬁed CRC-SCs in three categor-
ies according to their LY2606368-sensitivity: high sensitive,
medium sensitive, low sensitive/resistant, with approximately a
third of samples for each group (ﬁgure 1C and online
supplementary table S3). Administration of LY2606368
signiﬁcantly decreased the clonogenic potential of medium sen-
sitive and high sensitive but not that of resistant CRC-SCs
(ﬁgure 1D), and dwindled the fraction of cells expressing speciﬁc
colorectal CSC markers—CD44v6 and ephrin B2—or displaying
elevated WNT activity exclusively in LY2606368-sensitive
CRC-SCs (ﬁgure 1E and online supplementary ﬁgure S2).
Consistent with our in vitro approach, the in vivo growth of
#1-derived xenografts and, to a lesser extent, that of xenografted
#3 were arrested by the administration of LY2606368, whereas
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that of #8-derived xenografts was unaffected by LY2606368
(ﬁgure 1F). To conﬁrm the decrease in the CSC fraction by
LY2606368 administration, we recovered high sensitive CRC-SCs
from LY2606368-treated mice and reimplanted cells to form sec-
ondary heterotopic xenografts. Such tumours displayed less clo-
nogenicity and growth delay in comparison to those generated by
CRC-SCs recovered from vehicle-treated mice (ﬁgure 1G).
Taken together, these results demonstrate that LY2606368
efﬁciently targets a large subset of CRC-SCs in vitro and in vivo
by preferentially depleting CSCs.
Impact of DDR on LY2606368 sensitivity
When we correlated drug sensitivity with genome sequencing
data, we observed that mutations of TP53 were the most signiﬁ-
cant biomarker predicting CRC-SCs sensitivity to LY2606368
(p=0.001, Pearson’s χ2 test, all samples analysed) (ﬁgure 2).
However, a small percentage (20%, 4/20) of high sensitive and
medium sensitive CRC-SCs did not show TP53 mutation indi-
cating the existence of additional contributing factors.
To identify other clinically relevant pharmacodynamic
biomarkers of LY2606368 sensitivity, we thus performed a
time-course RPPA with a panel of antibodies covering
tumour-relevant pathways (see online supplementary table S4).
We found that the constitutional activation of the DDR was
crucial in conferring sensitivity to LY2606368 (ﬁgure 3A and
online supplementary ﬁgure S3). Indeed, basal levels of ATM and
ATR activating phosphorylation were signiﬁcantly higher in
LY2606368-high sensitive CRC-SCs than in LY2606368-
resistant ones (box plots on the left in ﬁgure 3B and online
supplementary ﬁgure S4). Moreover, LY2606368 administration
induced a speciﬁc time-dependent phosphorylation of ATM (but
not ATR) in LY2606368-responding (ie, high+medium sensitive)
cells but not in unresponsive CRC-SCs (kinetics on the right in
ﬁgure 3B and online supplementary ﬁgure S4) and an early
increase of CHK1 phosphorylation in all CRC-SCs analysed (see
online supplementary ﬁgure S4). A further investigation of the
status of the ATR-CHK1 and ATM-CHK2 axis by western blot
conﬁrmed the signiﬁcant high basal level of ATM phosphoryl-
ation in LY2606368-responding CRC-SCs as well as activation of
ATM on LY2606368 administration in high sensitive CRC-SCs
(ﬁgure 3C and online supplementary ﬁgures S5). Corroborating
the relevance of ATM, whole-exome sequencing performed in a
restricted number of CRC-SCs revealed that ATM was more fre-
quently mutated in resistant (4/5) than in medium (2/5) or high
sensitive (0/6) CRC-SCs (see online supplementary table S5).
Altogether, these ﬁndings indicate that the phoshorylation of
ATM is a potential marker of sensitivity to LY2606368 in CRC-SCs.
Basal levels of endogenous DNA damage dictate the
response of CRC-SCs to LY2606368
We then performed extensive analyses of DNA damage levels by
means of RPPA, western blot and immunoﬂuorescence studies.
These analyses revealed that basal phosphorylation levels of RPA2/
RPA32, a signalling intermediate of ongoing DNA replication stress
(RS) response,27 and H2A histone family, member X (γH2AX), a
double strand break (DSB)-sensitive marker, were signiﬁcantly
Figure 1 Identiﬁcation of LY2606368 (LY) as a potent anti-colorectal cancer stem cells (CRC-SCs) agent, both in vitro and in vivo. (A) Three
CRC-SCs (#1, #2 and #3) were left untreated or treated with a library of 305 compounds at 20 nM (see online supplementary table S2). After
72 hours, cell proliferation/viability was evaluated by means of CellTiter-Glo assay. Results are reported as means±SD of three technical replicates. In
the magniﬁcation on the right, the corresponding normalised viability values for the most active compounds are shown as standardised z scores.
Bortezomib, epothilone B and LY2606368 had the most potent anti-CSC activity as demonstrated by the reduction of cell viability below 50% or 3
SDs from the grand mean in all CRC-SCs analysed. (B and C) The depicted CRC-SCs (B,C) and American Type Culture Collection (ATCC) CRC cell
lines (C) were left untreated or administered with a dose range of 13 speciﬁc pharmacological inhibitors of DNA damage response (DDR) players (B),
or LY2606368 (C). Forty-eight hours (C) or 72 hours (B and C) later, CRC-SCs were assessed for their proliferation/viability by CellTiter-Glo assay. In
(B), a hierarchical clustering of logarithmic scaled IC50 values obtained from dose-response curves in online supplementary ﬁgure S1 is illustrated.
Panel (C) shows the dose-response curves of three representative CSCs (#1, #6 and #7) and a histogram reporting the IC50 values for the indicated
CRC-SCs (means±SEM; n≥2). Bright and dark colour scales refer to end points at 48 hours and 72 hours, respectively. CRC-SCs were classiﬁed in
three groups according to their sensitivity to LY2606368: high sensitive (IC50<100 nM at 48 hours and 72 hours of treatment), medium sensitive
(IC50>100 nM at 48 hours of treatment and <500 nM at 72 hours of treatment), low sensitive/resistant (IC50>500 nM at 48 hours and 72 hours of
treatment). (D) CRC-SCs from each class of LY2606368 sensitivity were left untreated or treated for 24 hours with LY2606368 at the depicted
concentrations. Upon drug washout, CRC-SCs were seeded at low cell density and subjected to soft agar assay to evaluate their clonogenic
potential. Cells were cultivated for up to 15 days in drug-free medium and then colonies were counted upon staining with crystal violet.
Representative images of colonies formed from LY2606368-sensitive and LY2606368-resistant CRC-SCs as well as quantitative data (means±SEM;
n≥3) obtained upon normalisation to plating efﬁciency of untreated cells are shown. At least three CRC-SCs from each group of LY2606368
sensitivity were employed. *p<0.05, **p<0.01, ***p<0.001 (two-way ANOVA and Bonferroni post hoc tests) as compared with the corresponding
untreated CRC-SCs. (E) CRC-SCs differing for their LY2606368 sensitivity were left untreated or administered with LY2606368 as depicted, and then
co-stained with the vital dye 4',6-diamidino-2-phenylindole (DAPI) and an antibody directed against the CRC-SC marker CD44v6 followed by
cytoﬂuorimetric analysis. Representative plots for one LY2606368-sensitive (#4) and one LY2606368-resistant (#7) CRC-SCs (numbers indicate the
percentages of corresponding events) as well as a histogram reporting quantitative data (means±SEM; n=4) concerning the fold change decrease of
CD44v6+ cells as compared with control conditions are reported. Only viable cells (ie, those excluding DAPI) were included in the analysis. At least
two CRC-SCs from each group of LY2606368 sensitivity were employed. *p<0.05, **p<0.01, ***p<0.001 (two-way ANOVA and Bonferroni post hoc
tests) as compared with the corresponding untreated CRC-SCs. AU, arbitrary units. (F) CRC-SC #1 (in vitro high sensitive), #3 (in vitro medium
sensitive) and #8 (in vitro low sensitive) were injected subcutaneously into immunodeﬁcient mice. When tumours were palpable, mice underwent
subcutaneous injections of captisol (vehicle/control group, NT) or LY2606368 at 5 mg/kg or 10 mg/kg (three cycles of three consecutive days, bis in
die, followed by 4 days of rest). Ten mice per group were employed. Arrows refer to LY2606368 injection. Tumour size was routinely monitored by
means of a common calliper. Results are reported as means±SEM. *p<0.05, **p<0.01, ***p<0.001 (two-way ANOVA and Bonferroni post hoc
tests) as compared with mice injected with the same CRC-SCs and treated with the vehicle. (G) CRC-SC #1-xenografted mice were treated as in (F).
Upon the last treatment tumours were recovered and re-injected in immunodeﬁcient mice (secondary xenografts). All secondary mice were left
untreated and tumour growth (means±SEM) was routinely evaluated by means of a common calliper. *p<0.05, **p<0.01, ***p<0.001 (two-way
ANOVA and Bonferroni post hoc tests) as compared with mice injected with #1-derived tumours recovered from vehicle-treated mice (NT). In (C–E)
LY2606368-high, LY2606368-medium and LY2606368-low sensitive CRC-SCs are depicted in red, yellow and green, respectively.
Manic G, et al. Gut 2017;0:1–15. doi:10.1136/gutjnl-2016-312623 5
GI cancer
group.bmj.com on February 14, 2018 - Published by http://gut.bmj.com/Downloaded from 
higher in LY2606368-sensitive than in LY2606368-resistant
CRC-SCs (box plots on the left in ﬁgure 4A–C and see online
supplementary ﬁgures S6–S8). These results indicate an elevated
amount of basal endogenous DNA damage and RS in these cells.
In addition, LY2606368 signiﬁcantly induced DNA damage (ﬁgure
4D) and increased the levels of RPA32 phosphorylation and
γH2AX in CRC-SCs (box plots on the right in ﬁgure 4A, B and see
online supplementary ﬁgure S6). IHC analyses performed on
parafﬁn-embedded sections of >15 CRC-SCs-derived xenografts
conﬁrmed a signiﬁcant association between LY2606368 sensitivity
and phosphorylation of ATM or RPA32 (p=0.043 or 0.013,
respectively; high+medium vs low) (ﬁgure 4E, F).
Altogether, these results indicate that high basal levels of RS
coupled to ATM phosphorylation represent reliable in vitro and
in vivo markers for predicting the response of CRC-SCs to
LY2606368.
Mechanisms of CSCs killing by, and of resistance to, LY2606368
We then explored the impact of LY2606368 on CRC-SC cell
cycle progression. We observed that LY2606368 affected cell
cycle distribution selectively in LY2606368-sensitive (high
+medium) CRC-SCs by enriching the percentage of cells with a
DNA content between 2n and 4n (ﬁgure 5A). S-phase accumula-
tion was accompanied by a signiﬁcant augmentation of the
mitotic cell fraction (pH3+) in high but not medium sensitive
or low sensitive CRC-SCs (ﬁgure 5A and online supplementary
ﬁgure S4E). Moreover, upon LY2606368 exposure a consider-
able percentage of pH3+ cells in high+medium sensitive
CRC-SCs displayed <4n DNA content, while the fraction of
premature mitoses did not signiﬁcantly vary among
LY2606368-unresponsive CRC-SCs (ﬁgure 5A). LY2606368
induced a signiﬁcant increase in the percentage of
DNA-replicating (5-ethynyl-20-deoxyuridine (EdU)+) cells only
in responsive CRC-SCs (ﬁgure 5B), suggesting the deregulation
of the replication process. These results, which are reminiscent
of those found in the absence of CHK1,23 28 indicate that
CHK1 is the main target of LY2606368. Accordingly, the deple-
tion of CHK1 induced an accumulation of cells with a DNA
content between 2n and 4n (ﬁgure 5C), triggered cell death
(ﬁgure 5D and see online supplementary ﬁgure S9), and
impaired the clonogenic potential (ﬁgure 5E) exclusively in
LY2606368-sensitive CRC-SCs. The absence of the
p53-dependant G1 checkpoint forces S-phase entry in the pres-
ence of DNA damage. In line with this evidence, the expression
levels of the p53 target cyclin-dependent kinase inhibitor 1A
(CDKN1A/p21) were higher in resistant than sensitive cells (see
online supplementary ﬁgure S10). This conﬁrms that p53 deﬁ-
ciency is a marker of LY2606368 sensitivity and that the p53
pathway protects from the lethal effect of LY2606368.
CRC-SCs responding to LY2606368 could not endure cell cycle
deregulation and eventually die for the activation of the caspase-
dependent pathway of apoptosis (ﬁgure 5F).
Altogether these results indicate that LY2606368 kills
CRC-SCs by inhibiting CHK1 resulting in the deregulation of
DNA replication, impairment of cell cycle checkpoints and
lethal replication catastrophe.
Figure 2 Oncoprint of mutations for the 16 most commonly mutated genes in colorectal cancer (CRC) found in CRC stem cells (CRC-SCs) by deep
sequencing1.
1http://cancer.sanger.ac.uk/cosmic, online supplementary table S1. 2No Catalogue Of Somatic Mutations In Cancer (COSMIC) mutations were found
for: ACVR1B, KIAA1804, MAP2K4, NRAS, SMAD2.
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Impact of the ploidy status on the sensitivity of CRC-SCs to
LY2606368
We then evaluated the impact of chromosomal content on
LY2606368 activity. Through metaphase spreading, we found a
heterogeneous modal chromosome number with ∼57% (13/23)
CRC-SCs exceeding the near-to-diploid set (>50, ie,
hyperdiploid) (ﬁgure 6A, B). Cell cycle proﬁling by ﬂow cyto-
metry conﬁrmed the signiﬁcant association between LY2606368
sensitivity and increased chromosome number (p=0.005;
Pearson’s χ2 test, high+medium vs low) (ﬁgure 6C–E). Thus,
almost all hyperdiploid CRC-SCs (∼95.2%, 20/21) were high
+medium sensitive to LY2606368, whereas 88.9% (8/9) of
Figure 3 Phosphorylation of ataxia telangiectasia mutated serine/threonine kinase (ATM) as a marker of colorectal cancer stem cells (CRC-SCs)
sensitivity to LY26063668. (A and B) Nine representative CRC-SCs, three from each group of LY2606368 sensitivity, and the ATCC cell lines HCT 116
and HT-29 were left untreated or treated with LY2606368 at low doses (10 nM, 50 nM and 100 nM) for 1 hour, 4 hours, 9 hours or 24 hours and
then subjected to reverse-phase protein microarray (RPPA) analysis. Panel (A) represents the hierarchical clustering of RPPA results obtained on
untreated CRC-SCs (white) and CRC-SCs exposed for 24 hours to 100 nM LY2606368 (black). In the left part of (B), basal levels of phosphorylated
(p)ATM (pATM_S1981) in untreated CRC-SCs at all time points were pooled for each sensitivity group and box-plotted. Statistical analysis: Wilcoxon
signed-rank test followed by p value adjustment by false discovery rate (FDR) for the comparison of high versus low sensitive CRC-SCs (*p<0.05,
**p<0.01, ***p<0.001). In (B), on the right, the full time-dependent and dose-dependent RPPA kinetics of pATM are shown as means±SD of
CRC-SCs grouped by LY2606368 sensitivity. Statistical analysis: factorial ANOVA design followed by p value adjustment (Tuckey’s honestly signiﬁcant
difference (HSD)) for the comparison of (1) 100 nM LY2606368-treated versus untreated CRC-SCs of the same sensitivity group (*p<0.05, **p<0.01,
***p<0.001) or (2) high versus low sensitive CRC-SC treated with 100 nM LY2606368 (§p<0.05, §§p<0.01, §§§p<0.001). A.U., arbitrary units. (C)
The illustrated CRC-SCs were left untreated (–) or administrated with 100 nM LY2606368 (LY) for 6 hours (+) and then subjected to western blot
analyses with antibodies recognising the phosphorylated or total forms of ATM, checkpoint kinase (CHK)2, ataxia telangiectasia mutated and Rad3
related serine/threonine kinase (ATR) or CHK1. Nucleolin or β-actin levels were monitored to ensure equal loading of lanes. Note that six CRC-SCs,
two from each sensitivity class, were the same used in RPPA studies. One representative western blot is shown. For the densitometric and statistical
analysis of the western blots, refer to online supplementary ﬁgure S5 and online supplementary information. LY2606368-high (H),
LY2606368-medium (M) and LY2606368-low (L) sensitive CRC-SCs are depicted in red, yellow and green, respectively.
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Figure 4 Endogenous DNA damage and replication stress predict the response of colorectal cancer stem cells (CRC-SCs) to LY2606368, both in vitro and
in vivo. (A–C) reverse-phase protein microarray (RPPA) box plots or time-response and dose-response plots (A and B) and western blot analyses (untreated
conditions) performed with antibodies recognising the phosphorylated (p) form of RPA32 (pRPA32_S4/S8) and total RPA32 (C) on a representative panel of
CRC-SCs. In (A) and (B), the box plots on the left represent basal levels of pRPA32_S4/S8 or γH2AX of untreated CRC-SCs pooled for each sensitivity group,
while line plots on the right report the RPPA kinetics of pRPA32_S4/S8, and γH2AX shown as means±SD of CRC-SCs grouped by LY2606368 sensitivity. For
more insights on RPPA data statistical analysis refer to legend of ﬁgure 3B. A.U., arbitrary units. In (C) β-actin levels were monitored to ensure equal
loading of lanes. One representative western blot is shown. For the densitometric and statistical analyses of the western blots, refer to online supplementary
ﬁgure S5 and online supplementary information. (D) CRC-SCs from each class of LY2606368 (LY) sensitivity were left untreated or treated for 24 hours with
100 nM LY2606368, and then subjected to single cell gel electrophoresis (also known as COMET assay) to measure DNA lesions. The panel shows
representative microphotographs of one sensitive CRC-SC (#4) and one resistant CRC-SC (#7) as well as box plots of the tail moments of at least 100 nuclei
per experimental point measured by image analysis. Scale bar=100 mm. Statistical analysis: Wilcoxon signed-rank test followed by p value adjustment by
false discovery rate (FDR) for the comparison of high versus low sensitive CRC-SCs (*p<0.05, **p<0.01, ***p<0.001). (E and F) Representative IHC images
obtained from CRC-SC-derived xenograft sections stained with antibodies recognising pRPA32_S4/S8 (E) and phosphorylated ATM (pATM_S1981) (F) (scale
bar=30 μm). Upon IHC analyses specimens were divided into two groups, one with low staining (pRPA32_S4/S8low or pATM_S1981low) and one with high
staining (pRPA32_S4/S8high or pATM_S1981high) according to the median intensity values and by scoring on a continuous scale of 0–300. Numbers in the
tables refer to the number (N) and the percentage (%) of samples in each group. The association between phosphorylation levels and LY2606368 sensitivity
in all samples was evaluated by Pearson’s χ2 test, whereas the comparison of high+medium (med) versus low sensitive CRC-SCs by Fisher’s exact test.
p values <0.05 were considered statistically signiﬁcant. LY2606368-high (H), LY2606368-medium (M) and LY2606368-low (L) sensitive CRC-SCs are
depicted in red, yellow and green, respectively.
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resistant CRC-SCs were near-to-diploid (ﬁgure 6D, E). As
opposed to ploidy, MSI status was not signiﬁcantly associated to
the response of CRC-SCs to LY2606368 (p=0.108; Pearson’s
χ2 test, high+medium vs low) (ﬁgure 6D). Consistent with the
role of p53 in controlling ploidy,29 ∼81% (13/16) of
TP53-mutated CRC-SCs were hyperdiploid, while ∼73% (8/11)
TP53 wild type CRC-SCs displayed near-to-diploid karyotypes
(association TP53 mutation and ploidy status: p=0.043;
Pearson’s χ2 test) (ﬁgure 2). Taken together these results indicate
that hyperdiploidy is a cytogenetic marker of LY2606368
sensitivity.
Strategies to modulate CRC-SC sensitivity to LY2606368
We ﬁnally assessed the relevance of the predictive markers iden-
tiﬁed above. We ﬁrst evaluated the impact of ATM activity dem-
onstrating that the pharmacological inhibition of ATM partially
protected medium/high sensitive CRC-SCs from LY2606368
(ﬁgure 7A). Thereafter, we assessed the contribution of p53
showing that the constitutive knockdown of p53 via transduc-
tion of shRNA-expressing lentiviral vectors sensitised previously
resistant CRC-SCs to LY2606368 (ﬁgure 7B). To analyse
whether an artiﬁcial increase in cellular ploidy might confer sen-
sitivity to LY2606368, we generated clones bearing a double
DNA content (hereafter called tetraploid) from one
p53-mutated (#14) and three p53-proﬁcient (#7, #8, #10)
near-to-diploid CRC-SCs with an optimised protocol.30 We
obtained two tetraploid clones only from CRC-SC #14, both
displaying an augmented sensitivity to LY2606368 (ﬁgure 7C).
Corroborating the positive impact of RS on LY2606368 sensitiv-
ity, by perturbing DNA replication with low/sublethal doses of
aphidicolin, hydroxyurea or thymidine, we were able to signiﬁ-
cantly sensitise previously non-responding CRC-SCs to
LY2606368 (ﬁgure 7D). Along similar lines, LY2606368
cytotoxicity was highly increased in LY2606368-resistant
CRC-SCs by coadministering gemcitabine (ﬁgure 7E).
These results conﬁrm the reliability of the phosphorylation of
ATM, p53 deﬁciency, hyperdiploidy and high RS as markers of
LY2606368 sensitivity, thus validating our experimental strategy.
DISCUSSION
In this study, after a pharmacological screening with therapeutic
compounds on CRC-SCs, LY2606368 was identiﬁed as a potent
anti-CRC-SC single agent acting independently of RAS muta-
tional status. We also demonstrated that CHK1 targeting by
LY2606368 potently killed CRC-SCs from approximately a
third of tumours by preferentially depleting the CSC fraction.
Cell death occurred via a mechanism involving the alteration
and deregulation of DNA replication, which resulted in the gen-
eration of an intolerable DNA damage burden and induction of
replication catastrophe.31 By correlating drug sensitivity with
data coming from genome sequencing, RPPA and cytogenetic
analyses, we identiﬁed four predictive and interlinked markers
of CRC-SC sensitivity to LY2606368: (1) high basal levels of RS
markers; (2) overactivation of the DDR player ATM; (3) muta-
tions of TP53; and (4) hyperdiploidy (ﬁgure 7F).
Compelling evidence indicates that the DDR acts as a barrier
during oncogenesis by limiting genomic instability induced by
RS.32 Deregulated DDR pathways are frequently found in human
neoplasms, where they are linked to increased genomic instability
and therapeutic failure and/or sensitivity.22 33 34 Moreover, it is
becoming evident that, once established, tumours overactivate
the DDR to endure high levels of RS.35 CSCs efﬁciently activate
the DDR24 25 and are responsible for tumour resilience. From a
therapeutic perspective, here, we demonstrated that CRC-SCs
displaying RS are highly dependent on the activity of CHK1, a
kinase frequently overexpressed in neoplasms and regulating
Figure 5 LY2606368 kills colorectal cancer stem cells (CRC-SCs) by inducing replication catastrophe and premature mitosis entry following
checkpoint kinase (CHK)1 inhibition. (A) CRC-SCs from each class of LY2606368 sensitivity were left untreated or treated for 6 hours or 24 hours
with LY2606368 at 10 nM or 100 nM, then ﬁxed with ethanol and stained with the DNA dye 4’,6-diamidino-2-phenylindole (DAPI) and an antibody
directed against phospho-histone H3 (pH3_S10), for cytoﬂuorimetric analysis of DNA content and mitotic cells. In the upper part, cell cycle proﬁles
and dot plots of pH3+ cells with the indicated DNA content are shown for one representative high sensitive and low sensitive CRC-SC. Orange and
red quadrants highlight premature mitosis (pH3+ cells with a <4n DNA content) and normal mitosis (pH3+ cells with a 4n DNA content) events,
respectively. Numbers indicate the percentages of corresponding events. The histograms report quantitative data (means±SEM; n=4; at least three
CRC-SCs from each group of LY2606368 sensitivity were employed) concerning the percentage or the fold change (as compared with control
conditions) of S-phase, pH3+ cells and premature mitosis. Note that the sub-G1 fraction was excluded from the analysis. *p<0.05, **p<0.01,
***p<0.001 (two-way ANOVA and Bonferroni post hoc tests) as compared with the corresponding untreated CRC-SCs. (B) CRC-SCs differing for
their LY2606368 sensitivity were left untreated or treated for 15 hours with LY2606368 as indicated, then ﬁxed and labelled with the thymidine
analogue 5-ethynyl-20-deoxyuridine (EdU). Representative dot plots of EdU+ cells for LY2606368-high sensitive CRC-SCs and quantitative data
(means±SEM; n=3; at least three CRC-SCs from each group of LY2606368 sensitivity were employed) for the three groups of sensitivity to
LY2606368 are reported. Note that the sub-G1 fraction was excluded from the analysis. *p<0.05, **p<0.01, ***p<0.001 (two-way ANOVA test
followed by Bonferroni post hoc test) as compared with the corresponding CRC-SCs left untreated. (C–E) CRC-SCs from each class of LY2606368
sensitivity were transfected with an unrelated small interfering (si) RNA (siCTR) or two speciﬁc siRNAs directed against CHK1 (siCHK1A and
siCHK1B) (C and E) or, alternatively were transduced with lentiviral vectors expressing non-silencing short hairpin (sh) RNA (shCTR) or
CHK1-targeting shRNAs (shCHK1A and shCHK1B) (D). Samples were collected, dissociated as single cells and then either analysed for their DNA
content by ﬂow cytometry upon staining with the DNA dye Hoechst 33342 (C), subjected to the cytoﬂuorimetric assessment of mitochondrial
membrane potential loss (a cell death-associated parameter) upon staining with Tetramethylrhodamine, methyl ester (TMRM) (D), or evaluated for
their clonogenic potential by soft agar assay (E) as described in ﬁgure 1D. At least two CRC-SCs from a distinct group of LY2606368 sensitivity were
employed in all the assays. Histograms reporting quantitative data (means±SEM; n≥3) concerning the percentage of S-phase cells or viable cells at
the indicated time upon transfection/transduction are shown in (C) or (D), respectively. ‘d2’ and ‘d7’ refer to the day after the puromycin selection
round. NT, non-transfected cells. In (C) the sub-G1 fraction was excluded from the analysis, while in (D) only the transduced cell population (green
ﬂuorescent protein+, GFP+ cells) was assessed. Quantitative data of clonogenicity (means±SEM; n≥2) obtained upon normalisation to plating
efﬁciency of siCTR-transfected CRC-SCs are shown in (E). *p<0.05, **p<0.01, ***p<0.001 (two-way ANOVA and Bonferroni post hoc tests) as
compared with the corresponding siCTR-transfected or shCTR-transduced CRC-SCs. (F) Reverse-phase protein microarray (RPPA) time-response and
dose-response plots of cleaved Caspase-3 (cCASP3), cleaved Caspase-7 (cCASP7), cleaved poly(ADP-ribose) polymerase 1 (cPARP-1) and cleaved
Fodrinα (cFODRINα) of CRC-SCs grouped by LY2606368 sensitivity. Results are shown as means±SD. For more insights on RPPA data statistical
analysis refer to legend of ﬁgure 3B. LY2606368-high, LY2606368-medium and LY2606368-low sensitive CRC-SCs are depicted in red, yellow and
green, respectively. A.U., arbitrary units.
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Figure 6 Hyperdiploidy is a cytogenetic marker of colorectal cancer stem cells (CRC-SCs) sensitivity to LY2606368. (A and B) A panel of CRC-SCs
displaying high, medium or low sensitivity to LY2606368 (total=23) was treated for 4 hours with 5 μM colchicine and then subjected to metaphase
spreading upon ﬁxation and staining with Hoechst 33342. Representative metaphase images of six CRC-SCs and dot plots reporting the modal
chromosome number (means±SEM; n=100) of all the CRC-SCs analysed are shown in (A) and (B), respectively. (C–E) A panel of CRC-SCs (total=38)
was dissociated as single cells and then either stained with the DNA dye Hoechst 33342 or ﬁxed with ethanol and stained with the DNA dye
propidium iodide (C–E). Alternatively, their DNA was extracted for determining microsatellite instability (MSI) status (D). Representative cell cycle
proﬁles of six CRC-SCs are shown in (C), while a table summarising the ploidy status, LY2606368 sensitivity and MSI status of all CRC-SCs analysed
is reported in (D). The statistical analysis of the association between ploidy and LY2606368 sensitivity is illustrated in (E). HCT 116 cells
(chromosome number=45; grey proﬁles) was used as internal diploid control. In (E), numbers in the table refer to the number (N) and the
percentage (%) of samples in each group. The association between ploidy status and LY2606368 sensitivity in all samples was evaluated by
Pearson’s χ2 test, whereas the comparison of high+medium (med) versus low sensitive CRC-SCs by Fisher’s exact test. p values <0.05 were
considered statistically signiﬁcant. The classes of sensitivity to LY2606368 are colour coded as follows: high/red, medium/yellow and low/green.
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DNA replication, RS response and cell cycle progression.36 37 We
surmise that the essential role of CHK1 in CRC-SCs is to main-
tain a high but tolerable level of RS (ﬁgure 7F). This ‘threshold
level’ hypothesis is supported by two observations. First,
LY2606368-mediated inhibition of CHK1 increased the level of
RS and induced a lethal replication catastrophe31 exclusively in
CRC-SCs responding to LY2606368. This occurred through a
mechanism involving: (1) unscheduled DNA replication accom-
panied by the slowing down of the replication process and RS,
ultimately leading to an excess of stretches of single-stranded
DNA recognised by phosphorylated RPA32;31 (2) the deregula-
tion of S-phase progression due to the impairment of the
CHK1-dependent intra-S checkpoint; and (3) replication fork
collapse eventually resulting in the accumulation of DSBs during
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replication. This evidence conﬁrms recent observations demon-
strating that CHK1, which is a key player for the correct execu-
tion and regulation of DNA replication, rather than CHK2,
which operates mainly during the G2-M transition, is the major
target of LY2606368.23 It also proves that LY2606368 induces
DNA damage and, at the same time, inhibits the DDR. Second,
strategies aimed at perturbing replication (eg, gemcitabine coad-
ministration) sensitised non-responding CRC-SCs to LY2606368.
These results, which are in line with previous observations,38 39
suggest that the activity of CHK1 becomes essential in CRC-SCs
as a means to cope with enhanced RS.
In this preclinical study, CRC-SC sensitivity to LY2606368 is
associated with the phosphorylation of ATM, suggesting a
crucial role of ATM in coordinating the RS response, which is
in line with previous ﬁndings.40 Accordingly, we found a signiﬁ-
cant association between the phosphorylation of ATM and
RPA32, and responsiveness of CRC-SCs to LY2606368. These
results conﬁrm the crosstalk between the ATM-CHK2 and
ATR-CHK1 cascade.27 Reportedly, ATR-CHK1 inhibitors dis-
played synthetic lethality with deﬁciency in other DDR
players.41 42 Here, we provide evidence that the inhibition of
ATM protects CRC-SCs to LY2606368, suggesting a functional
role of ATM in the mechanism of CRC-SC killing by
LY2606368. Further experiments are needed to elucidate the
precise link between ATM and CHK1.
We also provided evidence of a cytogenetic cause of RS in
tumours. CRC-SCs having a hyperdiploid chromosome set
showed higher levels of RS than near-to-diploid CRC-SCs, which
explains their exquisite sensitivity to LY2606368. We surmise
that the imbalance/augmentation in copy number of multiple
chromosomes is behind the increased RS displayed by hyperdi-
ploid cells.43 44 Moreover, a hyperdiploid karyotype may lead to
the deregulation of cancer-related proteins involved in RS
response. In this context, hyperdiploid CRC-SCs always harbour
mutation(s) in TP53, which may promote RS by favouring the
generation/tolerance of hyperdiploidy or diminishing DNA
repair efﬁciency. Accordingly, we demonstrated that the absence
of p53 signiﬁcantly increased the cytotoxicity caused by the
inhibition of CHK1. Moreover, the few diploid CRC-SCs sensi-
tive to LY2606368 mostly presented TP53 mutations and high
RS levels, while p53-proﬁcient near-to-diploid CRC-SCs consti-
tutionally activated the p53 pathway to limit RS and LY2606368
toxicity. These ﬁndings are coherent with previous observations
reporting enhanced sensitivity to CHK1 inhibition of tetraploid
and/or p53-deﬁcient cancer cells.45 46
Patient-derived cancer models are promising tools for drug
discovery and clinical efﬁcacy prediction.47–50 The major
strength of this preclinical study is the vast collection of molecu-
larly and functionally characterised CRC-SCs. This enabled us
to (1) identify a clinically relevant agent with broad anti-CSC
activity at low nanomolar doses, and effective against
KRAS-mutated, non-hypermutated and/or p53-deﬁcient
CRC-SCs, (2) uncover and validate in vitro and in vivo candi-
date predictive markers of CRC-SC responsiveness, and (3)
design strategies to overcome the intrinsic resistance to this
therapeutic regimen. Importantly, LY2606368 demonstrated tol-
erable safety proﬁles and preliminary evidence of antineoplastic
activity in a recent phase I, non-randomised, open-label,
dose-escalation trial in patients affected by advanced or meta-
static solid tumours who underwent at least three previous lines
of treatment.26 In this study, partial response and disease stabil-
isation was obtained in 4.4% and 33.3% of patients, respect-
ively. LY2606368 is currently employed alone or combined with
other therapeutic agents in ongoing phase I or phase II studies
also in patients with CRC (eg, NCT02203513, NCT02124148;
https://clinicaltrials.gov/). Our preclinical study supports the
further clinical development of LY2606368 as we demonstrated
its potent anti-CSC activity in a subset of CRC-SCs and uncov-
ered for the ﬁrst time biomarkers associated with its efﬁcacy in
CRC. The prospective validation of the predictive value of these
biomarkers may thus provide valuable background to the deﬁn-
ition of prediction nomograms. In this context, the identiﬁca-
tion of reliable markers of CSCs and enhanced/ongoing RS
response will allow to prospectively distinguish CSCs and
replication-stressed CSCs within the tumour mass and thus
conﬁrm the true potential of this anti-CSC strategy.
Figure 7 Strategies to modulate the sensitivity of colorectal cancer stem cells (CRC-SCs) to LY2606368. (A) Three representative LY2606368-high
or LY2606368-medium sensitive CRC-SCs were left untreated or were treated with LY2606368 and/or the ataxia telangiectasia mutated serine/
threonine kinase (ATM) inhibitor KU-60019 at the indicated dose. Upon 48 hours, CRC-SC proliferation/viability were assessed by CellTiter-Glo assay
(means±SEM; n=5). The percentage of viable cells shown for co-treatments with KU-60019 and LY2606368 is normalised over the correspondent
treatment with KU-60019 as single agent. Note that KU-60019 alone decreases CRC-SC viability of 0%, ∼9% and ∼27% at doses 1 mM, 5 mM and
10 mM, respectively. *p<0.05, **p<0.01, ***p<0.001 (two-way ANOVA and Bonferroni post hoc test) as compared with the corresponding
CRC-SCs left untreated or treated only with LY2606368. (B) Representative p53-proﬁcient CRC-SCs displaying resistance to LY2606368 (LY) were
transduced with lentiviral vectors expressing non-silencing short hairpin (sh) RNA (shCTR) or p53-targeting shRNAs (shp53A and shp53B). Upon
5 days of selection with 1.5 mg/mL puromycin, cells were ampliﬁed, seeded and then left untreated or treated with the indicated concentration of
LY2606368. Finally, cells were subjected to the assessment of mitochondrial membrane potential loss (a cell death-associated parameter) by ﬂow
cytometry upon staining with Tetramethylrhodamine, methyl ester (TMRM). Only the transduced cell population (GFP+ cells) was evaluated.
Representative plots (numbers refer to the percentage of TMRMlow cells), quantitative data (means±SEM; n≥3), and western blot analyses
performed with antibodies recognising the p53 or β-actin (whose levels were monitored to ensure equal loading of lanes) are reported. *p<0.05,
**p<0.01, ***p<0.001 (two-way ANOVA and Bonferroni post hoc tests) as compared with CRC-SCs transduced with the same shRNA but left
untreated. (C) CRC-SCs #14 were left untreated or treated with nocodazole for 48 hours, washed and then cultured in standard medium. Upon
2 weeks, cells were subcloned by limiting dilution to isolate diploid (2n) and tetraploid (4n) clones. The ploidy of proliferating clones was assessed
as in ﬁgure 6C. The IC50 values of the parental cells (#14), one diploid (#A1) and two tetraploid clones (#A2 and #A3) were calculated by
CellTiter-Glo assay after LY2606368 administration as indicated. Results from a single polyploidising series are reported. Note that following
∼30 days of culture #A2 and #A3 clones spontaneously reverted to near-to-diploidy decreasing their sensitivity to LY2606368. (D and E) Three
representative LY2606368-low sensitive CRC-SCs were left untreated or treated with the indicated concentration of LY2606368 alone or together
with sublethal doses of aphidicolin, hydroxyurea or thymidine (C), or three doses of gemcitabine (D). Cell viability, as assessed by CellTiter-Glo assay
after 72 hours of treatment, is reported as mean±SEM (n≥3). *p<0.05, **p<0.01, ***p<0.001 (two-way ANOVA and Bonferroni post hoc tests) as
compared with the corresponding CRC-SCs left untreated or treated only with LY2606368. (F) Proposed model accounting for LY2606368 sensitivity
of CRC-SCs. RS, replication stress; pATM, phosphorylated ATM; pRPA32, phosphorylated RPA32.
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